Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anticancer implant

A technology of implants and anti-cancer drugs, which is applied in the field of anti-cancer implants and can solve problems such as treatment failure and increased resistance to anti-cancer drugs

Inactive Publication Date: 2006-10-18
JINAN SHUAIHUA PHARMA TECH
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Not only that, the blood vessels in the tumor stroma are not sensitive to conventional chemotherapy drugs, which often leads to the enhancement of tumor cell resistance to anticancer drugs, and the result is treatment failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0092]Put 70 mg of polyglycolic acid and glycolic acid copolymer (PLGA, 65:35) with a peak molecular weight of 20000-40000 into a container, add 100 milliliters of dichloromethane, dissolve and mix well, then add 10 mg of colchicine (anti-mitotic drug) and 20mg5-FU (antimetabolite drug), re-shake well and then vacuum dry to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to prepare an anticancer implant containing 10% colchicine and 20% 5-FU. The drug release time of the anticancer implant in physiological saline in vitro is 15-25 days, and the drug release time of subcutaneous implantation in mice is 30-40 days.

Embodiment 2

[0094] The method steps of being processed into anticancer implants are the same as in Example 1, but the difference is that the anticancer active ingredients contained in the anticancer implants are:

[0095] 5-30% 6-mercaptopurine, 5-fluorouracil (5-FU), pemetrexed, pemetrexed disodium, lumitrexed, deoxyfluridine, fluoxuridine, mercaptopurine, thioguanine Purine, methotrexate, carmofur, tegafur, zalcitabine, emtricitabine, gallocitabine, ibacitabine, ancitabine, decitabine, flucitabine, Nortabine, Mizotabine, Mitoquinone, Mitotane, Cytarabine, Hydroxyurea, 5-Fluorouridine, Capecitabine, Gemcitabine, Fludarabine, Raltitridine, Raltitridine dexrazoxane, cladribine, noratrexed or pentasylate and 5-30% of cytochalasin, mitocloramine, mitorazone, mitoguanidine hydrazone, mitonaphthylamine, mitogen Hydrazine, Mitoquinone, Mitospex, Mitotane, Mitophenamine, Mitozolomide, Mitoransone, Colchicine Salicylate, Colchicine, Colcemid, Cell Relaxation Combinations of naphthol, naphthol, ...

Embodiment 3

[0097] Put 70mg of polylactic acid (PLGA, 50:50) with a peak molecular weight of 15000-25000 into a container, add 100ml of dichloromethane, dissolve and mix well, then add 20mg of pemetrexed (antimetabolite drug) and 10mg of Tumor mustard (nitrogen mustard drug), re-shake and vacuum-dry to remove organic solvents. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer implant containing 20% ​​of pemetrexed and 10% of Zormust. The drug release time of the anticancer implant in the physiological saline in vitro is 15-25 days, and the drug release time when placed subcutaneously in mice is 20-40 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The anticancer implant features the effective anticancer component coated inside the supplementary material to form slow released implant or slow released injection. The effective anticancer component is the composition of anticancer antimetabolite and its synergist. The synergist is selected from nitrogen mustard medicine, karyokinesis resisting medicine and / or plant alkaloid. The medicinal supplementary material is PLA, PLGA, EVAc, etc or their composition; the slow released injection consists of slow released microballoon and solvent; the solvent is common solvent or special solvent containing suspending agent; and the suspending agent is sodium carboxymethyl cellulose, mannitol, etc. Implanting or injecting the slow released preparation to local tumor part can lower the systematic toxic reaction of the medicine and raise the medicine concentration of local tumor part selectively to raise the treating effect.

Description

(1) Technical field [0001] The invention relates to an anticancer implant and belongs to the technical field of medicines. (2) Background technology [0002] Cancer treatment mainly includes surgery, radiotherapy and chemotherapy. Among them, surgical treatment not only cannot remove scattered tumor cells, so it often recurs or causes tumor cells to spread and metastasize due to surgical stimulation; radiotherapy and traditional chemotherapy are not selective, and it is difficult to form an effective drug concentration or therapeutic dose in the local tumor, resulting in poor efficacy and high toxicity. However, simply increasing the dose of drugs or radiation is limited by systemic toxicity. See Kong Qingzhong et al. "Intratumoral placement of cisplatin plus systemic carmustine to treat brain tumors in rats" "Journal of Surgical Oncology" 69 pages 76-82, 1998 (Kong Q et al., J Surg Oncol.1998Oct; 69( 2): 76-82). [0003] Local placement of antitumor drugs can better over...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/00A61K31/13A61K31/52A61K45/00A61K47/32A61K47/34A61K47/36A61K47/38A61K47/42
Inventor 孔庆伦
Owner JINAN SHUAIHUA PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com